Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Toyobo Co., Ltd. (3101.T)
Osaka, JP
Established in 1882 and headquartered in Osaka, Japan, Toyobo Co., Ltd. is a global enterprise delivering a diverse range of products. The company specializes in the manufacturing of films and advanced polymers, industrial components, healthcare solutions, and various textile goods. Its films and functional polymers division produces industrial PET films for applications such as liquid crystal displays and optics, in addition to synthetic papers. It also supplies a variety of packaging films, including PET, polyolefin, and nylon options for food products, along with heat-shrink PET films. The company's portfolio of functional polymers features engineering plastics, industrial adhesives, specialized coatings, photosensitive printing plates, acrylate polymers, and electronic materials. This segment further encompasses rubber and coat processing, as well as pharmaceutical intermediates. Within its industrial materials segment, Toyobo develops functional fibers for airbag construction, polyethylene fibers, and PBO fibers. It also creates functional filters for automotive and indoor environments, materials for anti-pollution solvent adsorption, and fiber components utilized in vehicle parts. In the healthcare sector, the company provides a comprehensive selection of bio-products, which includes enzymes for diagnostic purposes, diagnostic systems, and research reagents. Its contributions also extend to artificial kidney hollow fibers, anti-clotting substances, and seawater desalination modules. For textiles, Toyobo supplies functional fabrics suitable for sports clothing, undergarments, and uniforms, alongside synthetic filaments. The company markets apparel under its Munsingwear brand, acrylic fibers under Exlan, and acrylate fibers under the eks brand, while also engaging in general textile product commerce. Beyond these offerings, Toyobo serves as a contract manufacturer for injectable pharmaceuticals.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.04% | +15.61% | +16.71% | +11.03% | +40.02% | +35.69% | +86.99% | +67.42% | +24.89% | -8.99% | +28.65% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-0.1% Q1'26: +5.8% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+457.5% ★ Q1'26: +160.9% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+4.2% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+6.6% Q1'26: +8.4% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+4.3% Q1'26: +5.0% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.1% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×4.84× Q1'26: 3.90× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 4 EPS Ana. |
Mar 2027 3 Rev. Ana. 3 EPS Ana. |
Mar 2028 4 Rev. Ana. 4 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
351.28B
est: 352.16B (-0.3%)
|
347.76B
est: 356.83B (-2.5%)
|
329.49B
est: 333.75B (-1.3%)
|
331.15B
est: 336.43B (-1.6%)
|
336.70B
est: 340.37B (-1.1%)
|
339.61B
est: 340.40B (-0.2%)
|
337.41B
est: 335.98B (+0.4%)
|
375.72B
est: 371.70B (+1.1%)
|
399.92B
est: 401.77B (-0.5%)
|
414.27B
est: 422.38B (-1.9%)
|
422.03B
est: 432.80B (-2.5%)
|
428.09B
415.70B – 436.67B
-1.1% YoY
|
453.24B
440.38B – 458.20B
+5.9% YoY
|
471.01B
450.66B – 484.20B
+3.9% YoY
|
498.15B
480.26B – 507.93B
+5.8% YoY
|
522.70B
503.93B – 532.96B
+4.9% YoY
|
504.00B
485.90B – 513.89B
-3.6% YoY
|
| EBITDA |
35.87B
est: 25.78B (+39.2%)
|
37.79B
est: 26.12B (+44.7%)
|
38.48B
est: 24.43B (+57.5%)
|
39.82B
est: 24.63B (+61.7%)
|
37.67B
est: 24.91B (+51.2%)
|
39.80B
est: 24.92B (+59.7%)
|
45.75B
est: 24.59B (+86.0%)
|
48.51B
est: 27.21B (+78.3%)
|
29.11B
est: 29.41B (-1.0%)
|
28.80B
est: 54.85B (-47.5%)
|
39.35B
est: 56.20B (-30.0%)
|
55.59B
53.98B – 56.71B
-1.1% YoY
|
58.86B
57.19B – 59.50B
+5.9% YoY
|
61.17B
58.52B – 62.88B
+3.9% YoY
|
64.69B
62.37B – 65.96B
+5.8% YoY
|
67.88B
65.44B – 69.21B
+4.9% YoY
|
65.45B
63.10B – 66.74B
-3.6% YoY
|
| EBIT |
20.58B
est: 7.52B (+173.8%)
|
23.12B
est: 7.62B (+203.6%)
|
23.33B
est: 7.12B (+227.5%)
|
23.92B
est: 7.18B (+233.2%)
|
21.73B
est: 7.26B (+199.1%)
|
22.79B
est: 7.27B (+213.7%)
|
26.66B
est: 7.17B (+271.7%)
|
28.43B
est: 7.93B (+258.4%)
|
10.06B
est: 8.58B (+17.4%)
|
9.00B
est: 19.28B (-53.3%)
|
16.65B
est: 19.75B (-15.7%)
|
19.54B
18.97B – 19.93B
-1.1% YoY
|
20.69B
20.10B – 20.91B
+5.9% YoY
|
21.50B
20.57B – 22.10B
+3.9% YoY
|
22.74B
21.92B – 23.18B
+5.8% YoY
|
23.86B
23.00B – 24.32B
+4.9% YoY
|
23.00B
22.18B – 23.45B
-3.6% YoY
|
| Net Income |
8.12B
est: 7.39B (+9.9%)
|
10.15B
est: 11.70B (-13.3%)
|
9.44B
est: 10.03B (-5.8%)
|
13.04B
est: 18.26B (-28.6%)
|
-603.00M
est: 1.06B (-156.8%)
|
13.77B
est: 14.16B (-2.7%)
|
4.20B
est: 2.46B (+71.0%)
|
12.87B
est: 12.74B (+1.0%)
|
-655.00M
est: 7.59B (-108.6%)
|
2.46B
est: 3.75B (-34.5%)
|
2.00B
est: 2.51B (-20.3%)
|
9.15B
8.50B – 9.80B
+263.9% YoY
|
10.65B
7.94B – 12.18B
+16.4% YoY
|
12.67B
8.67B – 14.88B
+19.0% YoY
|
15.20B
12.00B – 18.41B
+19.9% YoY
|
17.00B
16.21B – 17.44B
+11.9% YoY
|
13.60B
12.96B – 13.94B
-20.1% YoY
|
| SGA |
45.55B
est: 55.76B (-18.3%)
|
45.44B
est: 56.50B (-19.6%)
|
45.24B
est: 52.85B (-14.4%)
|
46.89B
est: 53.27B (-12.0%)
|
48.39B
est: 53.89B (-10.2%)
|
50.06B
est: 53.90B (-7.1%)
|
51.14B
est: 53.20B (-3.9%)
|
53.99B
est: 58.85B (-8.3%)
|
60.93B
est: 63.62B (-4.2%)
|
63.61B
est: 67.28B (-5.5%)
|
66.04B
est: 68.94B (-4.2%)
|
68.19B
66.22B – 69.56B
-1.1% YoY
|
72.19B
70.15B – 72.99B
+5.9% YoY
|
75.03B
71.78B – 77.13B
+3.9% YoY
|
79.35B
76.50B – 80.91B
+5.8% YoY
|
83.26B
80.27B – 84.89B
+4.9% YoY
|
80.28B
77.40B – 81.86B
-3.6% YoY
|
| EPS |
91.40
est: 83.80 (+9.1%)
|
114.30
est: 132.75 (-13.9%)
|
106.40
est: 113.75 (-6.5%)
|
146.93
est: 207.09 (-29.1%)
|
-6.79
est: 12.04 (-156.4%)
|
155.12
est: 160.59 (-3.4%)
|
47.30
est: 27.88 (+69.7%)
|
144.75
est: 144.48 (+0.2%)
|
-7.37
est: 86.27 (-108.5%)
|
27.87
est: 42.53 (-34.5%)
|
22.72
est: 28.80 (-21.1%)
|
100.80
96.30 – 111.10
+250.0% YoY
|
122.05
90.03 – 138.05
+21.1% YoY
|
143.65
98.28 – 168.65
+17.7% YoY
|
172.35
136.00 – 208.70
+20.0% YoY
|
192.75
183.75 – 197.67
+11.8% YoY
|
154.10
146.90 – 158.03
-20.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus International Dividend ETF VDI | 0.24% | 38.3K | 0.39% |
| 2 | Dimensional - International Small Cap Value ETF DISV | 0.17% | 8.19M | 0.42% |
| 3 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.13% | 515.4K | 0.58% |
| 4 | Avantis International Small Cap Value ETF AVDV | 0.11% | 21.58M | 0.36% |
| 5 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.06% | 341.9K | 0.58% |
| 6 | iShares MSCI Japan Small-Cap ETF SCJ | 0.06% | 154.4K | 0.50% |
| 7 | Dimensional - International Small Cap ETF DFIS | 0.06% | 3.25M | 0.39% |
| 8 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.05% | 587.6K | 0.39% |
| 9 | State Street SPDR S&P International Small Cap ETF GWX | 0.05% | 457.9K | 0.40% |
| 10 | Avantis International Small Cap Equity ETF AVDS | 0.04% | 133.4K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chikao Morishige | EVice President, Assistant to the President, Chief Technology Officer and Head of Environmental & Functional Materials Division | — | male |
| Hidekazu Takahashi | Executive Officer & CFO | — | — |
| Ikuo Takeuchi | President, CEO, Head of Internal Audit, Co-COO & Representative Director | — | male |
| Masakazu Iwasaki | Managing Executive Officers & Head of Quality Assurance Division | — | — |
| Masanao Kudo | Managing Executive Officer, Co-COO, Head of Films Division & GM of Tokyo Branch | — | male |
| Seiji Narahara | Executive Chairman | — | male |
| Sonoko Ishimaru | General Manager of Corporate Communication Department & Executive Officer | — | male |
| Taichi Sakai | Senior Managing Exec. Officer, Co-COO & Rep. Director | — | male |
| Taizo Ono | Executive Officer, Chief Financial Officer & Head of Administration Division | — | male |
| Takahito Sagara | Managing Executive Officer, Head of Life Science Division & Director | — | male |
| Takayuki Tabo | Director | — | male |
| Takehiko Inada | Managing Executive Officer, GM of Human Resources, General Affairs & Legal Dept. | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3101.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
